Cargando…

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers

Aromatase, the rate-limiting enzyme in estrogen synthesis, is expressed in the ovaries of premenopausal, the placentas of pregnant women, and adipose tissue and skin cells in postmenopausal women, although to a lesser extent than in the ovaries. The direct mechanism of controlling breast cancer is t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cubbedge, Chandler, Perkins, Edward, Burak, William, Bose, Himangshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Tumor Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627972/ http://dx.doi.org/10.1210/jendso/bvac150.1794

Ejemplares similares

THU555 Stress Induced AIPB Expression In Triple Negative (ER-/PR-/Her2-) Breast Tumors Reduces Estradiol
por: Patrawala, Mahjabin, et al.
Publicado: (2023)

ODP433 An increased in AIPB expression in Triple Negative (ER-/PR-/Her2-) Breast Tumors reduces estradiol synthesis
por: Downs, William V, et al.
Publicado: (2022)

ODP540 Aromatase interacting partner in Breast (AIPB) regulates estradiol in human breast
por: Moffitt, Alyssa M, et al.
Publicado: (2022)

FRI407 Identification Of AIPB Expression For Early Breast Cancer Prediction
por: Doetch, Nicole Elizabeth, et al.
Publicado: (2023)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

THU539 Pembrolizumab-induced Hypophysitis Occurring Concurrently With Takotsubo Cardiomyopathy
por: Nadeem, Ifrah, et al.
Publicado: (2023)

ODP562 ZnT5 Involvement in EMT in Breast Cancer
por: Miki, Yasuhiro, et al.
Publicado: (2022)

ODP548 Fatty acid metabolism-related factors in breast and endometrial cancers
por: Miki, Yasuhiro, et al.
Publicado: (2022)

ODP541 Burr Under the Saddle: A Case of Sellar Plasmacytoma
por: Alkaissi, Hussam, et al.
Publicado: (2022)

ODP553 Hypoglycemia after sleeve gastrectomy: a rare case of an insulinoma
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2022)

ODP561 Unilateral Vestibular Schwannoma as the Presentation and Aggravation to be Severe Primary Hyperparathyroidism
por: Kiatpanabhikul, Phatharaporn
Publicado: (2022)

ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy
por: Chien, Christine, et al.
Publicado: (2022)

ODP559 The prognostic role of IL-17A-neutrophils crosstalk in triple-negative breast cancer
por: Khalid, Freeha, et al.
Publicado: (2022)

OR05-04 Steroid Receptor Co-Activators Complexes Cooperate with Progesterone Receptors (PR) to Reprogram Metabolic Pathways that Drive Therapy Resistant Populations in ER+ Breast Cancer
por: Truong, Thu H, et al.
Publicado: (2020)

ODP549 From Positive to Negative, a Histidine to Aspartic Acid Change in SDHB is Breaking Bad in Cardiac Paraganglioma
por: Harbuz-Miller, Inga, et al.
Publicado: (2022)

ODP550 Giant Cell Tumor of Bone: A Diagnostic Consideration of Sellar Lesions
por: Musa-Penna, Laurianne E, et al.
Publicado: (2022)

ODP543 Chemotherapy-induced extracellular HSP70 enhances pro-tumorigenic effects of macrophages in breast cancers.
por: Yamaguchi, Mio, et al.
Publicado: (2022)

ODP635 A rare case of metastatic papillary thyroid carcinoma on NTRK inhibitor with thyrotoxicosis
por: Fazeli, Sasan, et al.
Publicado: (2022)

ODP538 A Case of Multiple Endocrine Neoplasia Type 2A with Malignant Paraganglioma
por: Ozawa, Atsushi, et al.
Publicado: (2022)

ODP545 Ectopic Cushing's Syndrome in Small Cell Lung Cancer: A Frequently Missed Diagnosis
por: Iqbal, Qasim, et al.
Publicado: (2022)

ODP571 Blockade of ErbB-2 Nuclear Function Induces the Interferon Signaling Pathway in Breast Cancer Models Resistant to Trastuzumab
por: Elizalde, Patricia V, et al.
Publicado: (2022)

ODP551 Halting ErbB-2 Isoforms Retrograde Transport to the Nucleus as a New Theragnostic Approach for Triple Negative Breast Cancer
por: Elizalde, Patricia Virginia, et al.
Publicado: (2022)

ODP547 Familial Carney Complex: Follow Up of a Family With Negative PRKAR1A Genetic Screening
por: Araújo, Jacqueline Montalvão, et al.
Publicado: (2022)

ODP560 Thyroid Hormones membrane receptor, Integrin αvβ3, as a potential prognostic marker of chemotherapy response in breast cancer
por: Haedo, Mateo Campos, et al.
Publicado: (2022)

ODP544 Cumulative exposure of metabolic syndrome components and the risk of end-stage renal disease in the general population: a nationwide cohort study
por: Yoo, Soon Jib, et al.
Publicado: (2022)

THU559 3D Immuno-smFISH Reveals ER-responsive Cells At The Single-cell Level In ER(+) Breast Cancer
por: Kammel, Laura G, et al.
Publicado: (2023)

ODP558 Steroid Receptor Coactivators Promote Non-Small Cell Lung Cancer Tumorigenesis by Inhibiting Differentiation Factors, C/EBPα and NF-κB
por: Mendelson, Carole, et al.
Publicado: (2022)

SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2020)

OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2022)

OR05-05 Lethal ERα-Dependent Hyperactivation of the Unfolded Protein Response Induces Complete Regression Without Recurrence of Primary and Metastatic Breast Cancer
por: Duraki, Darjan, et al.
Publicado: (2020)

Steroid Receptor Co-Activators Regulate Metabolic Kinases to Drive Therapy Resistant ER+ Breast Cancer
por: Truong, Thu Ha, et al.
Publicado: (2021)

OR16-2 Steroid Receptor Co-Activator Complexes Regulate Metabolic PFKFB Enzymes to Drive Therapy Resistant ER+ Breast Cancer
por: Benner, Elizabeth, et al.
Publicado: (2022)

OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ERα Breast Cancer
por: Perone, Ylenia, et al.
Publicado: (2019)

OR16-06 A Novel Pathway Controlling Anticancer Drug Induced Immunogenic Necrosis In ERα Positive Cancer Cells
por: Zhu, Junyao, et al.
Publicado: (2023)

THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker
por: Gibbons, Erin, et al.
Publicado: (2023)

SAT-141 Glycoprotein NMB (GPNMB) Is Pro-Tumorigenic in TSC2-Null Cancer Cells and Is a Potential Drug Target and Biomarker for Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2020)

Digital Validation of Breast Biomarkers (ER, PR, AR and HER2) in Cytology Specimens Using Three Different Scanners
por: Salama, Abeer M., et al.
Publicado: (2021)

THU554 Unconventional Estrogen Receptor Antagonists Reveal Cryptic Therapeutic Anti-breast Cancer Transcriptional Pathways
por: Hancock, Govinda, et al.
Publicado: (2023)

THU546 A Lasofoxifene/Elacestrant Hybrid Antiestrogen Shows Effective Anti-tumoral Activities In Y537S ESR1 Breast Cancer Xenografts
por: Young, Kristen S, et al.
Publicado: (2023)

ERa-Dependent Lethal Hyperactivation of the Anticipatory Unfolded Protein Response Induces Complete Regression Without Recurrence of Advanced Breast Cancer
por: Duraki, Darjan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3hsn022u0hnocg335m5bv96ft6